Koers iteos therapeutics
WebApr 12, 2024 · Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist …
Koers iteos therapeutics
Did you know?
WebITeos Therapeutics has raised a total of $249.7M in funding over 8 rounds. Their latest funding was raised on Apr 1, 2024 from a Series B round. ITeos Therapeutics is registered under the ticker NASDAQ:ITOS . Their stock opened with $19.00 in its Jul 23, 2024 IPO. ITeos Therapeutics is funded by 17 investors. HBM Partners and Invus are the most ... WebDescription. ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
WebApr 13, 2024 · A high-level overview of iTeos Therapeutics, Inc. (ITOS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. WebFind the latest iTeos Therapeutics, Inc. (ITOS) stock quote, history, news and other vital information to help you with your stock trading and investing. iTeos Therapeutics, Inc. 321 Arsenal Street Suite 301 Building 312 Watertown, MA … Find the latest iTeos Therapeutics, Inc. (ITOS) stock discussion in Yahoo … Find the latest iTeos Therapeutics, Inc. (ITOS) stock quote, history, news and … See iTeos Therapeutics, Inc. (ITOS) stock analyst estimates, including earnings and … Get the detailed quarterly/annual income statement for iTeos Therapeutics, Inc. … iTeos to Present at Cowen 43rd Annual Health Care Conference. WATERTOWN, … Find out all the key statistics for iTeos Therapeutics, Inc. (ITOS), including … Find out the direct holders, institutional holders and mutual fund holders for … View the basic ITOS option chain and compare options of iTeos Therapeutics, … Get the latest iTeos Therapeutics, Inc. (ITOS) stock news and headlines to help …
WebJun 4, 2024 · About iTeos Therapeutics, Inc. iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno ... WebApr 12, 2024 · 125. Free-Float. 99,3%. More Financials. Company. iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. The Company’s pipeline includes two clinical-stage programs targeting novel ...
WebGuruFocus.com. Dec-09-21 04:01PM. iTeos Announces New Data for its Anti-TIGIT Antibody, EOS-448, at the American Society of Hematology Annual Meeting and TIGIT Therapies Digital Summit 2024. GlobeNewswire. Nov-22-21 10:38AM. Notable Iteos Therapeutics Insider Trades $1.1M In Company Stock. Benzinga. Nov-16-21 12:20PM. …
WebCompany Type For Profit. Phone Number 3271919934. ITeos Therapeutics is a private biotechnology company targeting the metabolism of the tumor microenvironment to … lambeth oneWeb94. Percentage vrij verhandelbaar. 99,7%. Meer Financiële cijfers. Bedrijfsprofiel. iTeos Therapeutics Inc. is een biofarmaceutisch bedrijf in een klinische fase. De Vennootschap … lambeth online parkingWebJun 4, 2024 · About iTeos Therapeutics, Inc. iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new … help album cover explainedWebMar 26, 2024 · The analysts covering iTeos Therapeutics, Inc. (NASDAQ:ITOS) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year ... lambeth older adults cmhtWebJun 14, 2024 · Shares of iTeos Therapeutics (ITOS 0.82%) surged 37% on Monday after it reached an agreement with GlaxoSmithKline (GSK 1.67%) to co-develop an experimental cancer treatment known as EOS-448. So what helpal gmbhWebJul 24, 2024 · Jul. 24, 2024, 04:06 AM. (RTTNews) - iTeos Therapeutics, Inc. announced that it has priced initial public offering of 10.59 million shares at $19.00 per share, above the estimated range. The ... lambeth online parking permitsWebMay 12, 2024 · Net Income/Loss: Net income attributable to common shareholders was $69.6 million, or net income of $1.96 per basic share and $1.82 per diluted share, for the quarter ended March 31, 2024, as ... lambeth old photos